AB Science Announces Publication of Three American Society of Clinical Oncology Presentations Detailing the Results of Masitinib in the Treatment of Advanced GIST

Published: Jun 05, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB) (NYSE Euronext-FR0010557264-AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces today that data from the development program of masitinib in gastrointestinal stromal tumors (GIST) have been presented as part of three presentations delivered at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, 1-5 June in Chicago, Illinois.

Back to news